Rocket Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
RCKT Nasdaq 2834 www.rocketpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rocket Pharmaceuticals, Inc.

Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug - Sep 18th, 2026 4:24 am
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease - Sep 16th, 2026 8:56 am
Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls - Sep 16th, 2026 7:42 am
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Airbnb, Booking Holdings, Credicorp, Dutch Bros, Expedia, Hartford Financial Services, Group, Meritage Homes, Patchex, Yum! Brands, and More - Sep 16th, 2026 6:07 am
Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock - Sep 16th, 2026 6:07 am
Rocket Pharmaceuticals Shares Rise 8% After FDA Alignment on Danon Disease Trial - Sep 15th, 2026 8:21 am
Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights - Sep 15th, 2026 8:12 am
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease - Sep 15th, 2026 5:00 am
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound? - Sep 11th, 2026 9:30 am
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report? - Sep 10th, 2026 9:30 am
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue? - Sep 9th, 2026 9:30 am
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - Sep 3rd, 2026 5:00 am
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus - Aug 11th, 2026 12:21 pm
Rocket Pharmaceuticals' Danon, PKP2-ACM Updates Seen as Key H2 Catalysts, Wedbush Says - Aug 11th, 2026 11:36 am
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress - Aug 10th, 2026 2:00 pm
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease - Aug 3rd, 2026 5:00 am
Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone? - Jun 25th, 2026 6:42 am
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million - Jun 12th, 2026 5:00 am
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going? - May 20th, 2026 6:35 am